Literature DB >> 325412

Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma.

A Yu, H Watts, N Jaffe, R Parkman.   

Abstract

The lack of detectable tumor-specific cytotoxicity by the peripheral blood lymphocytes of patients with cancer may be due to a lack of cytotoxic lymphocytes or the presence of suppressor lymphocytes that inhibit cytotoxic cells. Unfractionated peripheral blood lymphocytes from 12 of 28 patients with osteogenic sarcoma were cytotoxic to osteogenic sarcoma cells in vitro (P less than 0,001). When the peripheral blood lymphocytes from patients whose lymphocytes were not cytotoxic underwent fractionation, a tumor-specific cytotoxic subpopulation was isolated from 11 of 13 patients (P less than 0.0001). Lymphocytes that inhibited cytotoxic activity of autologous tumor-specific cytotoxic lymphocytes were found in four of 10 patients with osteogenic sarcoma but not in six normal controls. Inhibitor lymphocytes form rosettes with sheep erythrocytes and adhere to nylon, whereas cytotoxic lymphocytes have a receptor for C3 but no surface immunoglobulin. The lack of tumor-specific lymphocytotoxicity in some patients can be due to inhibitor lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 325412     DOI: 10.1056/NEJM197707212970301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  18 in total

1.  Cancer immunotherapy.

Authors:  R E Falk
Journal:  Can Med Assoc J       Date:  1979-02-03       Impact factor: 8.262

2.  Lymphocytes forming stable E-rosettes in acute and chronic hepatitis.

Authors:  M H Wansbrough-Jones; G H Scullard; A Nicholson; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1979-03       Impact factor: 4.330

Review 3.  Tumor dormancy: a review.

Authors:  E A Alsabti
Journal:  J Cancer Res Clin Oncol       Date:  1979       Impact factor: 4.553

4.  Suppressor-cell dysfunction in systemic lupus erythematosus. Cells involved and in vitro correction.

Authors:  A Sagawa; N I Abdou
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

5.  Induction of suppressor cell activities in normal lymphocytes by sera from gastric cancer patients.

Authors:  T Toge; M Tanada; K Yajima; H Kohno; E Itagaki; T Hattori
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

6.  Immunoregulation in hypersensitivity pneumonitis. I. Differences in T-cell and macrophage suppressor activity in symptomatic and asymptomatic pigeon breeders.

Authors:  R H Keller; J N Fink; S Lyman; G Pedersen
Journal:  J Clin Immunol       Date:  1982-01       Impact factor: 8.317

7.  Modifying the biological response in acute myeloid leukemia. II. Effect of BCG and leukemic cells on lymphocyte response to mitogens, and on helper and suppressor activity.

Authors:  A Arends-Merino; R Giscombe; C Ogier; P Reizenstein; A M Sjörgen; J Wasserman
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

8.  Survival after mastectomy for breast cancer: predictive value of lymphocyte count and its change after mastectomy in patients with metastases to one to three axillary nodes.

Authors:  K K Meyer
Journal:  World J Surg       Date:  1978-05       Impact factor: 3.352

9.  Lymphocyte blastogenic response to human thyroglobulin in Graves' disease, Hashimoto's thyroiditis, and metastatic thyroid cancer.

Authors:  N Aoki; J DeGroot
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

10.  Human-mouse mixed lymphocyte cultures. II. Partial separation of functionally distinct populations on discontinuous albumin gradients.

Authors:  A W Boylston; R L Anderson
Journal:  Immunology       Date:  1979-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.